In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

被引:990
作者
Tang, QZ
Henriksen, KJ
Bi, MY
Finger, EB
Szot, G
Ye, JQ
Masteller, EL
McDevitt, H
Bonyhadi, M
Bluestone, JA
机构
[1] Univ Calif San Francisco, UCSF Diabet Ctr, Dept Med, San Francisco, CA 94143 USA
[2] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA
[3] Xeyte Therap Inc, Seattle, WA 98104 USA
关键词
autoimmunity; tolerance; CD4(+)CD25(+)T cells; NOD mice; immunoregulation;
D O I
10.1084/jem.20040139
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The low number of CD4(+) CD25(+) regulatory T cells (T-regs), their anergic phenotype, and diverse antigen specificity present major challenges to harnessing this potent tolerogenic population to treat autoimmunity and transplant rejection. In this study, we describe a robust method to expand antigen-specific T-regs from autoimmune-prone nonobese diabetic mice. Purified CD4(+) CD25(+) Tregs were expanded up to 200-fold in less than 2 wk in vitro using a combination of anti-CD3, anti-CD28, and interleukin 2. The expanded T-regs express a classical cell surface phenotype and function both in vitro and in vivo to suppress effector T cell functions. Most significantly, small numbers of antigen -specific T-regs can reverse diabetes after disease onset, suggesting a novel approach to cellular immunotherapy for autoimmunity.
引用
收藏
页码:1455 / 1465
页数:11
相关论文
共 53 条
  • [21] An essential role for Scurfin in CD4+CD25+ T regulatory cells
    Khattri, R
    Cox, T
    Yasayko, SA
    Ramsdell, F
    [J]. NATURE IMMUNOLOGY, 2003, 4 (04) : 337 - 342
  • [22] CD25+CD4+ regulatory T cells prevent graft rejection:: CTLA-4- and IL-10-dependent immunoregulation of alloresponses
    Kingsley, CI
    Karim, M
    Bushell, AR
    Wood, KJ
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (03) : 1080 - 1086
  • [23] Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605
  • [24] TRANSFORMING GROWTH FACTOR-BETA-1 NULL MUTATION IN MICE CAUSES EXCESSIVE INFLAMMATORY RESPONSE AND EARLY DEATH
    KULKARNI, AB
    HUH, CG
    BECKER, D
    GEISER, A
    LYGHT, M
    FLANDERS, KC
    ROBERTS, AB
    SPORN, MB
    WARD, JM
    KARLSSON, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) : 770 - 774
  • [25] INHIBITION OF TRANSPLANT REJECTION FOLLOWING TREATMENT WITH ANTI-B7-2 AND ANTI-B7-1 ANTIBODIES
    LENSCHOW, DJ
    ZENG, YJ
    HATHCOCK, KS
    ZUCKERMAN, LA
    FREEMAN, G
    THISTLETHWAITE, JR
    GRAY, GS
    HODES, RJ
    BLUESTONE, JA
    [J]. TRANSPLANTATION, 1995, 60 (10) : 1171 - 1178
  • [26] Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice
    Lepault, F
    Gagnerault, MC
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (01) : 240 - 247
  • [27] Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function
    Levings, MK
    Sangregorio, R
    Roncarolo, MG
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) : 1295 - 1301
  • [28] Human CD25+ CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells
    Levings, MK
    Sangregorio, R
    Sartirana, C
    Moschin, AL
    Battaglia, M
    Orban, PC
    Roncarolo, MG
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (10) : 1335 - 1346
  • [29] The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens
    Lohr, J
    Knoechel, B
    Jiang, SW
    Sharpe, AH
    Abbas, AK
    [J]. NATURE IMMUNOLOGY, 2003, 4 (07) : 664 - 669
  • [30] Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes
    Masteller, EL
    Warner, MR
    Ferlin, W
    Judkowski, V
    Wilson, D
    Glaichenhaus, N
    Bluestone, JA
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (10) : 5587 - 5595